Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy. The study, conducted ...

June 5, 2002 -- Intravenous immunoglobulin (IVIG) is effective in treating some forms of diabetic-related neuropathy, according to results of a study published in the May issue of the Archives of ...

Please provide your email address to receive an email when new articles are posted on . In a case study of three patients with COVID-19 vaccine-induced immune thrombotic thrombocytopenia, starting ...

Please provide your email address to receive an email when new articles are posted on . IVIG had favorable effects on skin thickening, muscle and joint pain, and gastrointestinal symptoms of systemic ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment trials ...

NORFOLK, Va. — After a nationwide shortage of intravenous immunoglobulin (IVIG) medication, medical centers are now getting it back in stock. Patients at Sentara Health Care can now receive their ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Did you know that a component of your blood could be used ...

Immunoglobulin—one of nature's own defence mechanisms—is a highly effective treatment for a wide variety of inflammatory diseases, and has become an important but expensive weapon in the neurologist's ...

Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ...

IVIG has been used to treat AIN, but it is not always effective. We report a patient in which the concommitant use of IVIG and steroid was more effective than either alone. A 10 year old girl with ...

Aside from a reasonable safety profile, the first published Phase 2 study of a blood-derived antibody preparation to treat Alzheimer’s disease looks inconclusive at best. The six-month dose-finding ...